Navigation Links
Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Date:10/14/2010

ly supplemented with calcium and vitamin D.

In the pivotal study, serious infections leading to hospitalizations were reported more frequently in the Prolia-treated patient group. Serious skin infections, as well as infections of the abdomen, urinary tract and ear, were more frequent in patients treated with Prolia. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of severe infection, including cellulitis. Endocarditis was reported more frequently in the Prolia-treated patient group. Epidermal and dermal adverse events such as dermatitis, rashes, and eczema have been reported. Discontinuation of Prolia should be considered if severe symptoms develop.

Prolia resulted in significant suppression of bone remodeling. The significance of these findings is unknown. The long-term consequences of the degree of suppression of bone remodeling observed with Prolia may contribute to adverse outcomes such as osteonecrosis of the jaw (ONJ), atypical fractures, and delayed fracture healing. ONJ has been reported in patients with Prolia. Patients should be monitored for these adverse outcomes. The most common adverse reactions (> 5 percent and more common than placebo) were back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis. Pancreatitis has also been reported with Prolia.

About Denosumab CollaborationsIn July 2009, Amgen and GlaxoSmithKline (GSK) announced a collaboration agreement to jointly commercialize Prolia for postmenopausal osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize Prolia's postmenopausal osteoporosis and oncology indications in the U.S. and Canada and for all oncology indications in Europe and in other specified markets.

In addition, GSK will register and commercialize denosumab for all indications in countries where Amgen does not currently have a commercial presence,
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
2. Array BioPharma and Amgen Partner in Type 2 Diabetes
3. Amgen to Present at Lazard Capital Healthcare Conference
4. Amgen Announces Webcast of 2009 Third Quarter Financial Results
5. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
8. Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
9. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
10. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
11. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution ... pain management and clinical markets. The software increases the ... allowing users to highlight and review results that are ... analysts to filter results by group or based on ... the need to sift through analytes of no interest. ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5
... 2011 Bacterin International Holdings, Inc. (NYSE Amex: ... revolutionary bone graft material and antimicrobial coatings for medical applications, ... Healthcare Conference. The conference will be held at the Four ... Bacterin,s chairman and CEO, Guy Cook, and CFO, John ...
... NEWTOWN SQUARE, Pa., Aug. 24, 2011 Kibow Biotech, ... worldwide licensing and marketing agreement with the current licensing ... a patented, 100% natural, probiotic dietary supplement indicated for ... moderate to severe renal failure. Developed by Kibow, Azodyl™ ...
... generated stem cells from one of the most rapidly progressing ... into the condition as it will enable scientists to model ... certain nerve cells die. Scientists, funded with a 300,000 ... a patient diagnosed with one of the most progressive types ...
Cached Biology Technology:Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011 2Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement 2Stem cell study offers hope for Parkinson's patients 2
(Date:10/19/2014)... the last 30 years contributed only marginally to ... time, according to a new study published in ... access is fundamental to development: it brings improvements ... and health," says IIASA researcher Shonali Pachauri, who ... is widely agreed to be an important goal ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
(Date:10/16/2014)... Oregon and Washington land managers have a new synthesis ... eastside moist mixed-conifer (MMC) forests in the two states. ... Forests in Eastern Oregon and Washington: A Synthesis of ... Management, a general technical report published by the U.S. ... response to a request from managers for a synthesis ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... unique partnership between Syracuse University and the Serum Institute ... vaccines for children living in some of the most ... awarded $250,000 to a team of SU researchers led ... College of Arts and Sciences, to develop new oral ...
... America,s health! Water is essential to life, and one ... water safe from pathogens and other waterborne contaminants. Today, ... grants to four universities, one non-profit, and one research ... drinking water contaminants; including the harmful substances produced by ...
... have discovered a gene enhancer, known as HACNS1, that may ... thumb, and possibly also modifications in the ankle or foot ... a paper published in Science on Sept. 5, ... of the existence of human-specific gene enhancers, which are switches ...
Cached Biology News:Syracuse University partners with Serum Institute of India to develop vaccines for children 2Syracuse University partners with Serum Institute of India to develop vaccines for children 3Syracuse University partners with Serum Institute of India to develop vaccines for children 4To your health: EPA announces safe drinking water research 2Gene enhancer in evolution of human opposable thumb 2Gene enhancer in evolution of human opposable thumb 3
... Useful for the determination of digitonin and digoxin. ... EDTA Na 4 and 0.06% NaCl Preparation ... al., Biochem. Biophys. Res. Commun., 19, 755 ... mole of inorganic phosphorus from ATP per min ...
... 3C protease from human rhinovirus (HRV 3C) ... brand line of restriction grade proteases. The ... 6XHis-fusion protein, which recognizes the same cleavage ... small, 22 KDa size of the protease, ...
... Centra CL3 series is designed to ... and clinical applications at a reasonable ... includes quick connect rotors and various ... intuitive interface allows you to control ...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: